BOLD

Healthcare Biotechnology

Boundless Bio, Inc.

$2.58

-0.04 -1.53% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 11:00 AM ET	2.58

Key Stats

Market Cap

58.69M

Avg Volume

185,378

EPS

-$2.85

52W High

$3.16

52W Low

$0.96

Div. Yield

0.0%

Analyst Ratings

Hold

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-2.63

P/B Ratio

0.88

EV/EBITDA

0.20

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(67.9%)

Return on Assets

(32.8%)

Liquidity & Leverage

Current Ratio

9.48

Quick Ratio

9.35

Total Cash

72.63M

Total Debt

About

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

boundlessbio.com